Two questions related to reactions to carboplatin.
1. Are there any facilities or sites noticing an increase in reports of adverse drug reactions between brands of carboplatin? With the current carboplatin shortage, there is a perception with some of our infusion centers that the Teva product may be resulting in an increase in ADRs for patients.
2. Any measures other than the standard of hydration and pre-meds that your facility uses to mitigate reactions to carboplatin? For example, we have administration instructions for taxanes to gently invert the bag prior to administration because it is known taxanes can pool as a class of drugs.
Appreciate your input.